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Galectin 3 Induces a Distinctive Pattern of Cytokine and
Chemokine Production in Rheumatoid Synovial Fibroblasts via
Selective Signaling Pathways
Andrew Filer,1 Magdalena Bik,1 Greg N. Parsonage,1 John Fitton,1 Emily Trebilcock,1
Katherine Howlett,1 Michelle Cook,1 Karim Raza,1 David L. Simmons,2
Andrew M. C. Thomas,3 Mike Salmon,1 Dagmar Scheel-Toellner,1 Janet M. Lord,1
Gabriel A. Rabinovich,4 and Christopher D. Buckley1
Objective. High expression of galectin 3 at sites of
joint destruction in rheumatoid arthritis (RA) suggests
that galectin 3 plays a role in RA pathogenesis. Previous
studies have demonstrated the effects of galectins on
immune cells, such as lymphocytes and macrophages.
This study was undertaken to investigate the hypothesis
that galectin 3 induces proinflammatory effects in RA
by modulating the pattern of cytokine and chemokine
production in synovial fibroblasts.
Methods. Matched samples of RA synovial and
skin fibroblasts were pretreated with galectin 3 or tumor
necrosis factor  (TNF), and the levels of a panel of
cytokines, chemokines, and matrix metalloproteinases
(MMPs) were determined using enzyme-linked immuno-
sorbent assays and multiplex assays. Specific inhibitors
were used to dissect signaling pathways, which were
confirmed by Western blotting and NF-B activation
assay.
Results. Galectin 3 induced secretion of
interleukin-6 (IL-6), granulocyte–macrophage colony-
stimulating factor, CXCL8, and MMP-3 in both syno-
vial and skin fibroblasts. By contrast, galectin
3–induced secretion of TNF, CCL2, CCL3, and CCL5
was significantly greater in synovial fibroblasts than in
skin fibroblasts. TNF blockade ruled out autocrine
TNF-stimulated induction of chemokines. The MAPKs
p38, JNK, and ERK were necessary for IL-6 production,
but phosphatidylinositol 3-kinase (PI 3-kinase) was
required for selective CCL5 induction. NF-B activation
was required for production of both IL-6 and CCL5.
Conclusion. Our findings indicate that galectin 3
promotes proinflammatory cytokine secretion by tissue
fibroblasts. However, galectin 3 induces the production
of mononuclear cell–recruiting chemokines uniquely
from synovial fibroblasts, but not matched skin fibro-
blasts, via a PI 3-kinase signaling pathway. These data
provide further evidence of the role of synovial fibro-
blasts in regulating the pattern and persistence of the
inflammatory infiltrate in RA and suggest a new and
important functional consequence of the observed high
expression of galectin 3 in the rheumatoid synovium.
Rheumatoid arthritis (RA) is a persistent sys-
temic inflammatory disease characterized by inflamma-
tion involving multiple cell types, with the progressive
destruction of involved joints (1). An essential compo-
nent of the switch to persistence that underlies joint
destruction is the production of chemokines, which
recruit mononuclear cells, such as lymphocytes and
monocytes, to the inflamed joint (2). Galectins, an
evolutionarily conserved family of animal lectins, have
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diverse roles in cellular homeostasis and have been
shown to modulate inflammatory responses, functioning
as either proinflammatory or antiinflammatory regula-
tors, in part through their ability to cluster and modulate
signaling through glycan receptors associated with mul-
tiple ligands (3). This ability to influence immune re-
sponses has been demonstrated in animal models of a
number of diseases, including arthritis (4).
Galectin 3, a chimera-type member of the galec-
tin family, has a C-terminal carbohydrate recognition
domain responsible for carbohydrate binding but exhib-
its an N-terminal domain that is responsible for interac-
tions between subunits facilitating its oligomerization
(5,6). The biologic functions attributed to this lectin are
likely to depend on both ligand crosslinking and oli-
gomerization (6,7). Galectin 3 has been associated with
a proinflammatory role in models of fibrotic disease
affecting the lung and liver (8,9) and has been shown to
promote monocyte chemotaxis and macrophage activa-
tion (10–12) in addition to neutrophil activation, degran-
ulation, and superoxide production (13–15), suggesting a
critical role in the development of innate immune re-
sponses. Furthermore, a key role of galectin 3 has also
been shown in the survival and progression of tumor
metastases by modulating different processes, including
homotypic and heterotypic cell adhesion, migration,
angiogenesis, and tumor-immune escape (16).
In the context of synovitis, Ohshima and col-
leagues (17) have demonstrated increased levels of
galectin 3 and its binding protein in RA synovial tissue
compared with osteoarthritis (OA) synovial tissue. Fur-
thermore, galectin 3 levels are increased in RA in both
synovial fluid and peripheral blood compartments,
where levels correlate with C-reactive protein (17).
Interestingly, up-regulated expression of galectin 3 cor-
relates with abnormal cell apoptosis in synovial tissue
from patients with juvenile RA (18).
In contrast, galectin 1, a prototype member of the
galectin family composed of 1 conserved carbohydrate
recognition domain that can dimerize, has a predomi-
nantly antiinflammatory role, suppressing experimental
models of inflammatory diseases, such as hepatitis,
experimental autoimmune encephalomyelitis, uveitis,
colitis, and arthritis (19–22). Furthermore, this glycan-
binding protein appears to play an important role in the
mechanisms involved in Treg cell–mediated suppression
of immune responses (23), inhibition of T cell receptor–
mediated signal transduction (24), and differential reg-
ulation of T helper cell viability (25). Intriguingly, syno-
vial fibroblasts engineered to overexpress galectin 1
ameliorated collagen-induced arthritis and induced a
bias toward a Th2-mediated cytokine profile in vivo (22).
Synovial fibroblasts have an established role as
sentinel cells for immune cell activation in the joint (2),
and in RA, these cells are responsible for secreting
significant quantities of inflammatory cytokines (26).
RA synovial fibroblasts actively contribute to destruc-
tion of cartilage and bone via secretion of matrix met-
alloproteinases (MMPs) and cathepsins, and via expres-
sion of RANKL, resulting in promotion of monocyte-to-
osteoclast differentiation (27). The expanded population
of synovial fibroblasts in RA is also a prolific source of
chemokines responsible for the recruitment and reten-
tion of cells within the joint (2). It is clear that synovial
fibroblasts are an important source of galectin 3 within
the joint, as shown by messenger RNA (mRNA) and
proteomic analyses (17,28). Following stimulation by the
products of cartilage degradation, synovial fibroblasts
also produce galectin 3 (29). However, there are likely to
be many other sources of galectin 3 within the joint,
including macrophages, which synthesize this glycan-
binding protein in significant amounts (30).
Although considerable information is available
on the cellular sources of galectins in the synovium, the
downstream effects of galectin 3 on different cell types
in rheumatoid synovium remain largely unexplored. We
therefore examined the effects of exogenous galectin 3
on RA synovial fibroblasts, comparing them with genet-
ically matched control skin fibroblasts. We show that
inflammatory cytokines, such as interleukin-6 (IL-6),
and neutrophil-attracting chemokines, such as IL-8, are
produced equally by galectin 3– and tumor necrosis
factor  (TNF)–stimulated synovial and skin fibro-
blasts. However, in response to galectin 3, synovial
fibroblasts, but not skin fibroblasts, secrete mononuclear
cell–attracting chemokines such as CCL2, CCL3, and
CCL5. The molecular basis for this selectivity is due to
the differential activation of MAPK and phosphatidyl-
inositol 3-kinase (PI 3-kinase) signaling pathways in
response to galectin 3. The increased expression of
galectin 3 found in fibroblast-rich areas of the synovium
may therefore have significant functional consequences
in terms of recruitment of monocyte and lymphocyte
infiltrates.
MATERIALS AND METHODS
Media, antibodies, and cytokines. All tissue culture
reagents were purchased from Sigma (St. Louis, MO) unless
stated otherwise. Fibroblasts were cultured in RPMI 1640
supplemented with 1 mM sodium pyruvate, 1% nonessential
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amino acid solution, 10 mM glutamine, 100 g/ml of strepto-
mycin, 50 units/ml of penicillin, and 10% fetal calf serum. The
following signaling pathway inhibitors were used: BAY 11-
7085 (5 M; Alexis, Nottingham, UK), LY294002 (10 M;
Calbiochem, Abingdon, UK), bisindolylmaleimide I (2 M;
Calbiochem), Go¨6976 (10 nM; Calbiochem), SB202190 (10
M; Calbiochem), R406 (10 M; supplied by one of us [DLS;
Cellzome, Cambridge, UK]), and PD98059 (10 M; Cell Signal-
ing Technology, Beverly, MA). Anti-TNF blocking antibodies
(R&D Systems, Minneapolis, MN) were also used. Recombinant
proteins used were TNF (R&D Systems) and galectin 3
(PeproTech, London, UK).
Patients and fibroblast lines. Tissue samples were
collected from 8 patients who fulfilled the American College of
Rheumatology (formerly, the American Rheumatism Associ-
ation) 1987 revised criteria for RA (31). All patients exhibited
erosions on radiographs of the hands and feet; 7 of 8 patients
were rheumatoid factor positive. Tissue samples were also
obtained from 5 patients with radiographically confirmed OA.
Samples of synovium and overlying skin were obtained from
the knee joint of each patient at the time of joint replacement.
This study was reviewed and approved by the South Birming-
ham Local Ethics Committee (LREC 5735); all patients gave
written informed consent.
Tissue samples were minced into 1-mm3 sections
under sterile conditions, washed, and then resuspended in 10
ml of dissociation buffer (5 mM EDTA [Sigma] in phosphate
buffered saline [PBS]) and incubated for 2 hours at 4°C with
vigorous shaking. The resulting cell–tissue mixture was washed
3 times in fresh medium and then cultured until adherent
fibroblast colonies became confluent. Nonadherent cells and
tissue fragments were discarded once adherent cells had
appeared. Fibroblasts were expanded by trypsin digestion and
then reseeded into tissue culture flasks of twice the surface
area. Fibroblast phenotype was confirmed by morphologic
appearance and by immunofluorescence microscopy. All cells
expressed fibronectin and prolyl 4-hydroxylase, while 0.5%
of the cells stained positive for CD68, von Willebrand factor,
CD31, or cytokeratin. All experiments were performed with at
least 3 sets of matched fibroblast lines. All experiments used
fibroblasts between passages 2 and 6.
Fibroblast stimulation assays. Trypsinized fibroblasts
were seeded into flat-bottomed 96-well plates at a density of
6  103 cells/well and cultured for 48 hours. Culture medium
was then refreshed, and after pretreatment with medium,
blocking antibodies, signaling inhibitors, or DMSO carrier
control, the fibroblasts were exposed to different concentra-
tions of galectin 3 (0–10 g/ml) or to TNF (10 ng/ml) for 24
hours. Tissue culture supernatants were then collected and
stored at 80°C until analyzed. For inhibitor studies, the
numbers and morphology of the remaining adherent cells were
determined by Diff-Quick staining and microscopy, with 3 cell
counts per replicate, in order to rule out a direct toxic effect of
inhibitors on cell viability. Limulus amebocyte lysate assay of
recombinant galectin 3 indicated endotoxin levels that were
consistent with control medium, many fold below the manu-
facturer’s specification of 1 endotoxin unit/g (data not
shown).
Enzyme-linked immunosorbent assays (ELISAs). Tis-
sue culture supernatants were analyzed by ELISA for IL-6 and
CCL2 (monocyte chemotactic protein 1 [MCP-1]) using
OptEIA kits (PharMingen, Oxford, UK) as well as for CCL5
(RANTES) using a DuoSet kit according to the recommenda-
tions of the manufacturer (R&D Systems). The lower limits of
detection for the ELISA kits used were as follows: for IL-6, 15
pg/ml; for CCL2, 2 pg/ml; and for CCL5, 16 pg/ml.
Multiplex cytokine assays. Multiple cytokines were
analyzed simultaneously in supernatant samples using 15-plex
cytokine and chemokine kits and 3-plex MMP kits (BioSource,
Fleurus, Belgium) to measure levels of basic fibroblast growth
factor, granulocyte–macrophage colony-stimulating factor
(GM-CSF), granulocyte colony-stimulating factor, vascular
endothelial growth factor (VEGF), interferon- (IFN),
IFN, IL-1, TNF, CCL5, CCL3, CCL4, CXCL1, CXCL8,
CXCL9, CXCL10, MMP-3, MMP-9, and MMP-13. The assay
was performed using a Luminex 100 System, according to the
recommendations of the manufacturer (Upstate Biotechnol-
ogy, Lake Placid, NY).
Western blot analysis. Fibroblasts were washed with
PBS and lysed with 100 l of sodium dodecyl sulfate (SDS)
loading buffer. Lysates were heated for 10 minutes at 100°C
and stored at 20°C until further use. Proteins were separated
on 12% SDS–polyacrylamide gel electrophoresis gels at 40V
and then transferred to a 0.45-m polyvinylidene difluoride
membrane (Flowgen, Nottingham, UK) at 450 mA using a wet
blotting system (Bio-Rad, Richmond, CA). The membranes
were blocked with 5% bovine serum albumin (BSA) in Tris
buffered saline (TBS) with 0.1% Tween for 1 hour at room
Figure 1. Production of proinflammatory cytokines and matrix met-
alloproteinases in synovial and skin fibroblasts after stimulation with
galectin 3. Matched samples of synovial and skin fibroblasts from
patients with rheumatoid arthritis were seeded and treated with
medium (control) or recombinant galectin 3 (10 g/ml). A, Production
of interleukin-6 (IL-6) in synovial and skin fibroblasts after 24 hours of
stimulation, as analyzed by enzyme-linked immunosorbent assay. B–D,
Production of granulocyte–macrophage colony-stimulating factor
(GM-CSF) (B), matrix metalloproteinase 3 (MMP-3) (C), and tumor
necrosis factor  (TNF) (D) in synovial and skin fibroblasts after 24
hours of stimulation, as analyzed by multiplex bead assay. Bars show
the mean and SD of duplicate assays combined from at least 3 patients.
  P  0.05;   P  0.01, versus control medium.
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temperature. The following specific primary antibodies were
diluted in 0.1% Tween–TBS with 1% BSA: Akt/protein kinase
B (Transduction Laboratories, Lexington, KY); phospho-Akt,
p44/42 (ERK-1/2), and phospho-p44/42 (Cell Signaling Tech-
nology); p38, phospho-p38, and JNK1 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA); and phospho-JNK (Promega, Madison,
WI). The membranes were incubated with appropriate anti-
body overnight at 4°C with shaking and then washed 3 times for
15 minutes and incubated for 1 hour with species-specific
horseradish peroxidase–conjugated secondary antibody (Am-
ersham Biosciences, Roosendaal, The Netherlands) diluted to
1:5,000. After washing 3 times, the membranes were devel-
oped with an enhanced chemiluminescence system (Amer-
sham Pharmacia Biotech, Little Chalfont, UK) and exposed on
Kodak X-Omat LS film. The blots were scanned using a Syn-
gene gel documentation system (Syngene, Cambridge, UK).
NF-B activation assay. To assess the activation of
transcription factor NF-B (p65 subunit), nuclear extracts
from galectin 3 or TNF-stimulated fibroblasts were prepared
using a Nuclear Extract kit according to the recommendations
of the manufacturer (Active Motif, Rixensart, Belgium). The
protein content of each sample was measured by bicinchoninic
acid assay (Pierce, Rockford, IL), and equal amounts of
protein were obtained from each sample to perform the
TransAM p65 assay (Active Motif). The TransAM kit uses
96-well microtiter plates coated with an oligonucleotide con-
taining the NF-B consensus-binding sequence. The active
form of the p65 subunit in whole cell lysates was detected using
antibodies specific for an epitope that is accessible only when
the subunit is activated and bound to its target DNA. Detec-
tion of the activated DNA-bound form of p65 was performed
according to the recommendations of the manufacturer, and the
results were calculated as the fold increase compared with
unstimulated cells.
Statistical analysis. Nonparametric distribution was
assumed for all assays. For the difference between paired
(stimulation, inhibitor, and blockade) experiments, signifi-
cance was assessed using the Wilcoxon signed rank test with
2-tailed P values. Results are shown as the mean  SD or the
mean SEM where appropriate.
RESULTS
Production of proinflammatory cytokines and
MMPs in both synovial fibroblasts and skin fibroblasts
after stimulation with galectin 3. We first investigated the
effects of stimulation with exogenous recombinant galectin
3 on synovial fibroblasts by measuring the production of a
panel of cytokines, growth factors, and MMPs. By using
genetically matched skin fibroblasts (as control fibroblasts),
we eliminated the confounders that are frequently present
in studies of fibroblast lines obtained from different sub-
jects of widely varying age, disease subtype, and prior
Figure 2. Selective production of chemokines capable of attracting a mononuclear cell population in synovial fibroblasts, but not skin fibroblasts,
after stimulation with galectin 3. Matched samples of synovial and skin fibroblasts from patients with rheumatoid arthritis were seeded and treated
with medium (control), recombinant galectin 3 (10 g/ml), or recombinant tumor necrosis factor  (TNF; 10 ng/ml). Galectin 3 induced the
production of chemokines in synovial fibroblasts only, while TNF induced the production of chemokines in all fibroblasts regardless of tissue of
origin. A–D, Production of CXCL8 (A and B) and CCL2 (C and D) in synovial and skin fibroblasts after 24 hours of stimulation with galectin 3 (A
and C) or TNF (B and D), as analyzed by multiplex bead assay. E–H, Production of CCL3 (E and F) and CCL5 (G and H) in synovial and skin
fibroblasts after 24 hours of stimulation with galectin 3 (E and G) or TNF (F and H), as analyzed by enzyme-linked immunosorbent assay. Bars
show the mean and SD of duplicate assays combined from at least 5 patients.  P 0.05;  P 0.01;  P 0.001, versus control medium.
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therapy. Galectin 3 stimulated significant increases in levels
of IL-6, GM-CSF, andMMP-3 production by both synovial
and skin fibroblasts (Figures 1A–C) in a manner similar to
that seen with TNF stimulation (32). Unexpectedly, a
small, but consistent, quantity of TNF was secreted by
synovial fibroblasts, but not skin fibroblasts, stimulated
with galectin 3 (Figure 1D).
Selective production of mononuclear cell–
attracting chemokines in synovial, but not skin, fibro-
blasts after stimulation with galectin 3. To determine
whether galectin 3 affected the production of chemo-
kines associated with the arthritogenic process, we ana-
lyzed chemokine production in synovial fibroblasts com-
pared with matched skin fibroblasts. Stimulation with
galectin 3 greatly increased levels of secretion of CXCL8
(IL-8), a prototypic neutrophil chemoattractant, from
both synovial and skin fibroblasts (Figure 2A). In com-
plete contrast, increased levels of chemokines responsi-
ble for the recruitment of mononuclear cell populations
(e.g., CCL2, CCL3, and CCL5) were produced by galec-
tin 3–stimulated synovial fibroblasts only (and not by
skin fibroblasts) (Figures 2C, E, and G). In particular,
significant levels of CCL5 were seen only in RA synovial
fibroblasts stimulated with 10 g/ml of galectin 3.
Of note, a concentration of 10 g/ml was selected
because it corresponds to levels recently found to be
pathologically relevant in an experimental model of
Crohn’s disease (33). The effect of galectin 3 was
titratable (Figure 3) and became saturating beyond the
chosen concentration of 10 g/ml. CCL5 production was
very low in RA skin fibroblasts and was absent in 2 of the
4 lines tested. OA synovial fibroblasts stimulated with
galectin 3 produced both IL-6 and CCL5, but in lesser
quantities than did RA synovial fibroblasts (Figure 3).
Similar results were also seen for CCL4; results for other
cytokines, chemokines, and growth factors are shown in
Table 1.
Chemokine production in both synovial and skin
fibroblasts after stimulation with TNF. In order to
confirm that the differential production of these chemo-
kines in synovial fibroblasts, but not skin fibroblasts, was
not due to any intrinsic differences in the fibroblasts
from the 2 different sites, both synovial and skin fibro-
blasts were exposed to 10 ng/ml of TNF before collec-
tion of supernatants for analysis. Results confirmed that
TNF was capable of the generic induction of chemo-
kines in all fibroblasts regardless of tissue of origin
(Figure 2). This finding suggested that the induction of
mononuclear cell–attracting chemokines by synovial fi-
broblasts was a selective property of the biology of these
fibroblasts as compared with skin fibroblasts when stim-
ulated specifically with galectin 3.
TNF induction by galectin 3 is not the mecha-
nism underlying selective chemokine secretion. The
production of low levels of TNF in galectin
Figure 3. Effect of galectin 3 concentration on interleukin-6 (IL-6)
and CCL5 production in rheumatoid arthritis (RA) skin fibroblasts,
osteoarthritis (OA) synovial fibroblasts, and RA synovial fibroblasts.
Skin, OA synovial, and RA synovial fibroblasts were seeded and
treated with recombinant galectin 3 at the concentrations shown.
Production of IL-6 (A) and CCL5 (B) after 24 hours of stimulation was
analyzed by enzyme-linked immunosorbent assay. Bars show the mean
and SD of duplicate assays combined from at least 4 patients.   P 
0.05;   P  0.01, versus OA and skin fibroblasts stimulated with 10
g/ml of galectin 3.
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3–stimulated synovial fibroblasts but not in galectin
3–stimulated skin fibroblasts suggested that the differ-
ential ability of synovial fibroblasts to respond to galec-
tin 3 might be through the production of TNF promot-
ing chemokine secretion via an autocrine mechanism.
We therefore pretreated fibroblast cultures with a block-
ing antibody to TNF before exposing synovial fibro-
blasts to either TNF (10 ng/ml) or galectin 3 (10 g/ml)
(Figure 4). While IL-6, CCL2, and CCL5 secretion was
completely abrogated by antibody blockade when cells
were exposed to TNF, no effect was seen in response to
galectin 3 stimulation (Figure 4). These findings ruled
out the possibility that autocrine production of TNF by
synovial fibroblasts might regulate the differential pro-
duction of chemokines induced by galectin 3.
Regulation of synovial fibroblast production of
IL-6 and CCL5 via distinct signaling pathways. In order
to explore the molecular basis of the distinct pattern of
chemokine secretion observed in synovial fibroblasts
stimulated with galectin 3, we used signaling inhibitors
that have been shown to block candidate pathways in the
fibroblast inflammatory program. For this purpose, IL-6
and CCL5 were measured as a prototype cytokine and
mononuclear chemokine, respectively. Notably, we ob-
served involvement of the MAPKs p38, JNK, and
ERK-1 in IL-6 secretion, as shown by pharmacologic
Table 1. Cytokine, chemokine, and growth factor levels in galectin 3–stimulated and unstimulated RA synovial and skin fibroblasts*
Analyte concentration, pg/ml
RA synovial fibroblasts RA skin fibroblasts
Unstimulated Galectin 3–stimulated Unstimulated Galectin 3–stimulated
bFGF 10 10 10 10
G-CSF – – – –
VEGF 10.1–50 50.1–100 – 10
IFN – – – –
IFN – – – –
IL-1 10 10 10 10
CCL4 10 10.1–50 10 10
CXCL1 10 10.1–50 – 10
CXCL9 10.1–50 10.1–50 10.1–50 10.1–50
CXCL10 – 10 – –
MMP-9 10 10 10 10
MMP-13 – – – –
* Supernatants from rheumatoid arthritis (RA) synovial fibroblasts were cultured in medium alone (unstimulated) or with 10 g/ml of galectin 3,
and were assayed by multiplex enzyme-linked immunosorbent assay (ELISA) for cytokines and chemokines, and by ELISA for IL-6 (lower detection
limit 15 pg/ml). Duplicate wells for each sample were analyzed. Values are those obtained after background levels were subtracted. bFGF  basic
fibroblast growth factor; G-CSF granulocyte colony-stimulating factor; – undetectable or1 pg/ml; VEGF vascular endothelial growth factor;
IFN  interferon-; MMP-9  matrix metalloproteinase 9.
Figure 4. Tumor necrosis factor  (TNF) induction by galectin 3 (gal-3) is not the mechanism underlying selective chemokine secretion by
synovial fibroblasts. Synovial fibroblasts from patients with rheumatoid arthritis (RA) were seeded and treated with medium (control), recombinant
TNF (10 ng/ml), or recombinant galectin 3 (10 g/ml). Duplicate wells of cytokine-treated fibroblasts were pretreated with an anti-TNF blocking
antibody. A, Production of interleukin-6 (IL-6), a representative proinflammatory cytokine, after 24 hours of stimulation, as analyzed by
enzyme-linked immunosorbent assay (ELISA). B and C, Production of CCL2 (B) and CCL5 (C), representative chemokines, after 24 hours of
stimulation, as analyzed by ELISA. Bars show the mean and SD of duplicate assays combined from at least 4 patients.   P  0.01.
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intervention with SB202190, R406, and PD98059, re-
spectively (34,35) (Figure 5A). In addition, the use of
BAY 11-7085, an irreversible inhibitor of TNF-induced
IB phosphorylation (36), indicated that NF-B was an
important downstream mediator of IL-6 production by
synovial fibroblasts (Figure 5A). Bisindolylmaleimide I
is a broad-range inhibitor of the protein kinase C (PKC)
family of signaling molecules, while Go¨6976 selectively
inhibits classic PKC isoenzymes ( and ), allowing
dissection of the contribution of different PKC family
members to signaling cascades (34). However, no effect
of these inhibitors was seen.
Notably, LY294002, an inhibitor of PI 3-kinase
that acts upstream of Akt (37), and BAY 11-7085
significantly decreased levels of secretion of the chemo-
kine CCL5, suggesting participation of PI 3-kinase and
NF-B in CCL5 production by fibroblasts. Thus, while
NF-B appears to be a key common pathway in the
secretion of both inflammatory chemokines and cyto-
kines, upstream pathways controlling the selective secre-
tion of chemokines (PI 3-kinase) and cytokines (MAPK)
do not appear to overlap significantly. Since signaling
pathway inhibitors have the potential to affect cell
viability via off-target effects, we carefully monitored the
effect of inhibitors on fibroblast number and morphol-
ogy. No effect was seen on these parameters at the
concentrations of inhibitors used in these assays (data
not shown).
Activation of selective signaling pathways in ga-
lectin 3–stimulated synovial fibroblasts. In order to
dissect the molecular mechanisms involved in galectin 3
modulation of cytokine and chemokine secretion, we
analyzed the relevant signaling pathways that were
shown to be important in IL-6 and CCL5 secretion.
Western blotting was used to assess phosphorylation and
activation of ERK, JNK, and p38 MAPKs, with activa-
tion of ERK MAPK evident within 5 minutes of galectin
3 stimulation, and definite phospho-JNK and phospho-
p38 evident by 15 minutes (Figures 5C–E). Akt phos-
phorylation, consequent upon PI 3-kinase activation,
was also evident by 15 minutes (Figure 5F). In order to
independently confirm NF-B activation, nuclear ex-
tracts from galectin 3–stimulated synovial fibroblasts
were tested for binding of the activated p65 NF-B
subunit to an NF-B consensus sequence using an
NF-B ELISA kit. Figure 5G shows that similar fold
changes in binding of active p65 subunit were seen with
both TNF and galectin 3 treatment.
Figure 5. Regulation of synovial fibroblast production of IL-6 and CCL5 via distinct signaling pathways. Synovial fibroblasts from patients with
RA were seeded and treated with either DMSO carrier control or the specified pathway inhibitors for 1 hour. All wells were then treated with
recombinant galectin 3 (10 g/ml). A and B, Production of IL-6 (A) and CCL5 (B) after 24 hours of stimulation, as analyzed by ELISA. Bars show
the mean and SD of duplicate assays combined from at least 3 patients. C–F, Western blots of cell lysates of synovial fibroblasts obtained from
patients with RA and stimulated with galectin 3 for the indicated time periods. Cell lysates were labeled using primary antibodies to ERK (C),
JNK (D), p38 (E), and Akt (F) and their active phosphorylated forms. Results are representative of 4 lines or are from 4 lines combined. G,
Binding of the activated p65 NF-B subunit to an NF-B consensus sequence in nuclear extracts from RA synovial fibroblasts stimulated with
medium (control), TNF (10 ng/ml), or galectin 3 (10 g/ml), as analyzed using a TransAm NF-B ELISA kit. Bars show the mean and SD.
  P  0.05;   P  0.01;   P  0.001, versus DMSO or control medium. Bis  bisindolylmaleimide I; NS  not significant (see Figure
4 for other definitions).
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DISCUSSION
The recruitment and retention of a cellular infil-
trate rich in hematopoietic cells, such as monocytes,
lymphocytes, and granulocytes, is critical to the persis-
tence of inflammation in the RA synovium. Synovial
fibroblasts play a central role in the survival of a variety
of hematopoietic cell subpopulations (32,37–39). The
role of cytokine-stimulated fibroblasts in elaborating
chemokines is well documented, including recent data
demonstrating selective pathway activation by IL-18 in
the induction of CXCL12 (stromal cell–derived factor
1), CCL2, and VEGF (40).
Synovial fibroblasts are subject to a proinflamma-
tory cytokine network with direct cell contact with other
infiltrating cells, such as T lymphocytes (41,42), leading
to high levels of expression of many inflammatory
chemokines. Monocytes and T cells appear to be re-
cruited by a range of CXC and CC chemokines found at
high levels in the synovium. For example, CCL2
(MCP-1) produced by synovial fibroblasts is considered
to be a prototypical chemokine for the recruitment of
monocytes (43,44). CCL3 (macrophage inflammatory
protein 1 [MIP-1]), CCL4 (MIP-1), and CCL5
(RANTES) are chemotactic for monocytes and lympho-
cytes, are expressed at high levels in inflamed rheuma-
toid synovium and are also produced by synovial fibro-
blasts (45,46). Fibroblasts are therefore an important
cell type in the switch to persistent inflammation, since
they respond to many hematopoietic cells and their
derived cytokines by secreting a range of proinflamma-
tory cytokines and chemokines that recruit and maintain
the inflammatory infiltrate (2).
Our findings extend the range of factors to which
synovial fibroblasts respond to include galectin 3. Little
is known about the effects of galectins on fibroblast
biology in the synovium. Galectin 9 has recently been
shown to exert a proapoptotic effect on synovial fibro-
blasts from RA synovium and has been shown to be
present at high levels in RA synovial fluid. Furthermore,
previous studies have demonstrated that recombinant
galectin 9 ameliorates disease in mice with collagen-
induced arthritis through modulation of the balance of
Th17 and Treg cells (47,48). It is therefore clear that
galectins may play both proinflammatory and antiin-
flammatory roles in the RA synovium.
A paracrine role for galectin 3 has been shown
previously, demonstrating a proproliferative effect on
fibroblasts via cell surface carbohydrate receptors (49).
Lippert et al (33) identified galectin 3 as a protein
present in conditioned media from colonic epithelial
cells that is responsible for lamina propria fibroblast
IL-8 secretion and NF-B activation. Notably, the galec-
tin 3 activity detected in their assays was equivalent to
10 g/ml of recombinant protein, indicating that the
concentration chosen for our assays was biologically
relevant.
Janelle-Montcalm and colleagues (50) have dem-
onstrated a direct pathogenetic role of galectin 3 in
models of arthritis by injecting exogenous galectin 3
into the knee joints of mice. Galectin 3 induced knee
swelling and resulted in changes in the histologic scores
of cartilage and subchondral bone. In vitro studies of chon-
drocytes demonstrated induction of the proteoglycan-
degrading enzymes ADAMTS-5 and MMP-3, while in
osteoblasts, production of osteocalcin was inhibited with
involvement of the PI 3-kinase and ERK pathways (50).
No analysis of synovial fibroblasts was performed, but
these findings clearly demonstrate an important role for
galectin 3 in the modulation of inflammatory pathways
in stromal cells of the joint, leading to production of,
among other factors, MMPs, a finding we confirmed in
the present study (Figure 1C).
Data concerning the signaling pathways used by
galectin 3 to achieve its various biologic effects are
beginning to emerge. Signaling of galectin 3 via PI
3-kinase has been demonstrated in macrophages, where
an autocrine feedback loop is implicated in alternative
macrophage activation (12). Galectin 3 also plays impor-
tant roles in tumor cell survival and metastasis. Bladder
carcinoma cells are protected against apoptosis via PI
3-kinase/Akt pathway up-regulation, which is abolished
in galectin 3–deficient cells (51). MAPK activation has
also been shown to be a component of galectin 3
signaling; exogenous galectin 3 regulates neutrophil
apoptosis via p38 phosphorylation (14), while ERK
MAPK is one of a group of genes that are up-regulated
in the galectin 3–mediated progression of lung carci-
noma (52). Galectin 3 may also play a role in the
induction of JNK protein via increased transcription or
mRNA stabilization, as demonstrated by JNK deficiency
in mast cells from galectin 3–null mutant mice (53). The
PI 3-kinase and MAPK pathways thus appear to be the
major mediators of galectin 3 signaling. The findings of
the present study show that this extends to effects on
cytokine and chemokine secretion.
Our results are consistent with those of previous
studies of the regulation of chemokine secretion by PI
3-kinase and MAPK pathways. PI 3-kinase is frequently
implicated in the production of mononuclear cell–
attracting chemokines such as CCL2 and CCL5 in
stromal cells. PI 3-kinase and JNK are implicated in
IL-18 regulation of CCL2 production by synovial fibro-
blasts, whereas JNK has been implicated in VEGF
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production (40). Although TWEAK induction of CCL5
in osteoblasts occurs via PI 3-kinase independently of
NF-B, suggesting that the NF-B transcription pathway
may be partially redundant (54), our data suggest a
major role of both PI 3-kinase and NF-B in galectin 3
induction of CCL5. Moreover, given that the percentage
inhibition by the inhibitors we used was 50% and
70%, respectively (Figure 5A and B), and that signal-
ing pathway inhibitors such as LY294002 have variable
target specificities (34), it is possible that additional
pathways may be involved.
The 3 MAPK pathways are pivotal in proinflam-
matory cytokine activation of synovial fibroblasts and
other RA synovial cells (55), with TNF, IL-1, and IL-6
all capable of activating the 3 main pathways (56).
Previous work using knockout mice demonstrated that
JNK MAPK is crucial to the production of MMPs such
as the collagenases, which corresponds to our findings
(57). Similarly, ERK MAPK is implicated in the regula-
tion of IL-6 and TNF secretion in other cell types (56).
The p38 MAPK has also been implicated in the regula-
tion of MMPs by synovial fibroblasts (58).
A key finding of the present study is the signifi-
cant difference observed in the activation of regulatory
pathways for cytokine and chemokine production after
stimulation with galectin 3 in synovial fibroblasts but not
skin fibroblasts. This offers a convincing explanation for
the differences in leukocyte subsets observed between
inflamed synovial and skin lesions and suggests that
galectin 3 specifically drives a highly active PI 3-kinase
pathway exclusively in synovial fibroblasts. Our results
indicate that RA synovial fibroblasts are more respon-
sive to galectin 3 stimulation than are OA fibroblasts,
which is consistent with a role of galectin 3 in the
persistence of inflammation in the RA synovium, where,
in contrast to OA tissue, high levels of galectin 3 are
seen (17). The selective activation of the PI 3-kinase
signaling pathway provides further evidence to support
the concept that synovial fibroblasts display a unique
phenotype and provides a rational target for site-specific
therapy based on PI 3-kinase inhibition in synovial
fibroblasts (59). In conclusion, our data represent the
first evidence that galectin 3 plays a selective role in
modulating cytokine and chemokine production by syno-
vial fibroblasts, thus illuminating a novel target for
intervention in RA patients.
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